MY ACCOUNT | NEWSLETTER |

US fast-food brands make little progress towards improving chicken welfare standards


"The Pecking Order 2021" ranked how global fast-food restaurants are performing regarding the well-being of chickens in their global supply chains. In addition to the global ranking, this year, World Animal Protection released several country-specific reports ranking the companies based on their efforts. These reports show the wide differences in welfare commitments by region and the overall failure globally to set and work toward global commitments.

For the US rankings, half of the eight companies observed (KFC, Nando's, Domino's, and Pizza Hut) scored 'very poor'—the bottom rank—meaning consumers may be unknowingly buying meat from chickens that are subjected to unnecessary cruelty. This includes living in cramped and bare environments with no sunlight. Many will suffer from lameness and skin lesions before being killed. 

The other half of companies studied (Starbucks, Subway, Burger King, and McDonald's) ranked in the 'making progress' tier. However, no company has risen as a positive example for chicken welfare in the US market.

Currently, an estimated 60 billion chickens around the world each year live in cruel conditions in factory farms. They are given around 40 days to live until they are slaughtered when they are still effectively chicks. During that time, they are genetically tweaked to develop unnaturally fast, which places unnatural pressure on their hearts, lungs, and legs. As a result, they often live their short lives in chronic pain, suffering from lameness, skin lesions, and even heart failure.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

One Committed and Caring NC State Veterinary Student, So Many Choices

Like0
Dislike0

Dentalis Earns 5 VOHC® Seals, Positioning for Global Expansion in Animal Health

Like0
Dislike0

Advancing the 3Rs: innovation, implementation, ethics and society

Like0
Dislike0

Automated Knowledge-Based Radiation Treatment Planning in Canine and Feline Nasal Tumors

Like0
Dislike0

Does Lung Function Imaging Modality Have a Dosimetric Impact On Functional Avoidance Treatment Planning: Assessment Using Prospective Clinical Trial Data

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top